AGM Statement

Proteome Sciences plc

                                             PRESS RELEASE

For immediate release                                                                    4th July 2005

                                             AGM STATEMENT

At  the  Annual General Meeting of Proteome Sciences plc ("the Company") being held at 10.30am  today,
the following statement will be read out by Steve Harris, Chairman:

"As stated in the Annual Report for 2004, the Board believes that the Company's general prospects
remain most promising. Progress continues to be made in concluding the licence agreement for the
Company's Mass Tandem Tags® technology, and a strong expansion of commercial activity from the three
main divisions of the business is still expected."
                                                 ENDS

For further information please contact:

Proteome Sciences plc                             
www.proteomics.com                                
Christopher Pearce, Chief Executive               Tel: [phone]
                                                  Email: [e-mail]

Public Relations for Proteome Sciences            
IKON Associates                                   
Adrian Shaw                                       Tel: [phone]
                                                  Mobile: [phone]
                                                  Email: [e-mail]

Notes to Editors:

Proteome  Sciences  plc applies high sensitivity proteomics to identify and characterise  differential
protein  expression in diseases for diagnostic, prognostic and therapeutic applications.   It  has  to
date  developed  sensitive  blood assays for stroke, vCJD, BSE, solid organ transplant  rejection  and
Alzheimer's   disease.   The   main   focus  of  its  research   currently   addresses   neurological,
neurodegenerative, diabetes/obesity, oncology and cardiovascular conditions.

In  addition to its own proprietary biomarkers, Proteome Sciences has developed ProteoShop®  (Proteome
Sciences High Output Proteomics), a tool box that offers high sensitivity and high throughput gel  and
gel-free  proprietary technologies for the identification of potential biomarkers  and  drug  targets.
These include specialisation in membrane proteins and protein phosphorylation.

The  Company  has developed a range of specialist reagents to improve the performance and quantitation
of  protein  separation  and characterisation with mass spectrometry, bioinformatics,  statistics  and
pattern recognition. These include Sensitizer®, PST® qPST® and TMT®.

Commercialisation  is  actively  pursued  across  the  portfolio  of  the  Company's  programmes   and
technologies with licensing deals signed in biomarkers for Stroke and TSEs and for ProteoShop®.

Proteome Sciences is headquartered in Cobham, Surrey in the UK and has laboratories at King's  College
Hospital,  London and in Frankfurt.  It employs 40 full time scientists, in addition to its  corporate
and business development staff.  The Company is listed on the Alternative Investment Market.

Proteome Sciences